Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775565 · ClinicalTrials.gov registry record
Initial Experience With the AngioVac Venous Drainage Cannula
A clinical trial of Heart Disease, sponsored by Angiodynamics.
- Completed
- Registry status
- 51
- Enrollment target
- 5
- Study locations
NCT02775565 is a study of Heart Disease that has completed, run by Angiodynamics. The registered enrollment target is 51 participants, below the 2,045-participant average among 31 other Heart Disease trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02775565, a study of Heart Disease, has completed, sponsored by Angiodynamics.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a retrospective, record-based study of approximately 100 patients across up to 12 centers within the United States. All patients who have been treated with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit will be considered for study participation. Eligible subject must meet all of the inclusion criteria and none of the exclusion criteria to be considered enrolled in the study. The purpose of the study is to describe initial experience with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit.
Conditions Studied
Interventions
- DEVICE AngioVac
Study Locations (5)
California
- Providence St. Joseph - Burbank
- UCLA - Los Angeles
North Dakota
- Sanford Research - Fargo
South Carolina
- MUSC - Charleston
Washington
- Swedish Health Services - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775565
The ClinicalTrials.gov registry entry for NCT02775565 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,045-participant average among 31 other Heart Disease trials with a reported enrollment target (98% lower). The listed sponsor is Angiodynamics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which AngioVac is the first listed.
NCT02775565 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, North Dakota, South Carolina.
Frequently Asked Questions
What is clinical trial NCT02775565 about?
NCT02775565 is a clinical study titled "Initial Experience With the AngioVac Venous Drainage Cannula". This is a retrospective, record-based study of approximately 100 patients across up to 12 centers within the United States. All patients who have been treated with the AngioVac Venous Drainage Cannula and the Extracorporeal Circuit will be considered for study participation. Eligible subject must me...
What is the current status of trial NCT02775565?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2016-02. Estimated completion is 2017-05.
What conditions does trial NCT02775565 study?
This clinical trial studies the following conditions: Heart Disease.
What interventions are being tested in trial NCT02775565?
The interventions under investigation include: AngioVac (DEVICE).
Who is sponsoring clinical trial NCT02775565?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02775565 being conducted?
This trial has 5 study locations across California, North Dakota, South Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studies of Neuregulin/ERBB Signaling in Human Heart
RECRUITING
-
Promoting Physical Activity and Fitness Among Underserved Latino Families Living in U.S.-Mexico Border Regions
RECRUITING · NA
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Personalized Environment and Genes Study
RECRUITING
-
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
RECRUITING · NA
-
Heart Disease of the Small Arteries in Women and Men
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.